260 related articles for article (PubMed ID: 26514880)
21. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.
Andersen JT; Sandlie I
Drug Metab Pharmacokinet; 2009; 24(4):318-32. PubMed ID: 19745559
[TBL] [Abstract][Full Text] [Related]
22. Chimerism of avian IgY-scFv and truncated IgG-Fc: A novel strategy in cross-species antibody generation and enhancement.
Ge S; Dias ACP; Zhang X
Immunology; 2024 May; 172(1):46-60. PubMed ID: 38247105
[TBL] [Abstract][Full Text] [Related]
23. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein.
Cox GN; Smith DJ; Carlson SJ; Bendele AM; Chlipala EA; Doherty DH
Exp Hematol; 2004 May; 32(5):441-9. PubMed ID: 15145212
[TBL] [Abstract][Full Text] [Related]
24. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
25. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
26. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
27. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
28. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
30. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand.
Sánchez LM; Penny DM; Bjorkman PJ
Biochemistry; 1999 Jul; 38(29):9471-6. PubMed ID: 10413524
[TBL] [Abstract][Full Text] [Related]
31. Development of new models for the analysis of Fc-FcRn interactions.
Gurbaxani BM; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1379-89. PubMed ID: 16183124
[TBL] [Abstract][Full Text] [Related]
32. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
33. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
34. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.
Qiu Y; Lv W; Xu M; Xu Y
J Control Release; 2016 May; 229():37-47. PubMed ID: 26988600
[TBL] [Abstract][Full Text] [Related]
35. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
37. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
[TBL] [Abstract][Full Text] [Related]
38. A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
Unverdorben F; Hutt M; Seifert O; Kontermann RE
PLoS One; 2015; 10(10):e0139838. PubMed ID: 26430884
[TBL] [Abstract][Full Text] [Related]
39. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.
Low SC; Nunes SL; Bitonti AJ; Dumont JA
Hum Reprod; 2005 Jul; 20(7):1805-13. PubMed ID: 15817590
[TBL] [Abstract][Full Text] [Related]
40. Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.
Monnet C; Jorieux S; Urbain R; Fournier N; Bouayadi K; De Romeuf C; Behrens CK; Fontayne A; Mondon P
Front Immunol; 2015; 6():39. PubMed ID: 25699055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
